Licensing status

Publication and contact information

Infectious disease

Influenza virus

Influenza virus neuraminidase

In vitro, cell culture and mouse studies suggest covalent neuraminidase inhibitors could be useful for treating influenza infection. In vitro, a class of 2,3-difluorosialic acid derivatives showed longer-lasting inhibition of neuraminidase activity than the marketed neuraminidase inhibitors Relenza zanamivir and Tamiflu oseltamivir. In cell culture, the lead compound showed more potent inhibition of Relenza-resistant influenza A virus and influenza B virus than Relenza. In a mouse model for lethal influenza infection, the lead compound decreased viral load and increased survival with an effect comparable to that of Relenza. Next steps include out-licensing and preclinical development of the lead compound.
Relenza is marketed by GlaxoSmithKline plc and Biota Pharmaceuticals Inc. to treat and prevent influenza A.
Tamiflu is marketed by Roche and Gilead Sciences Inc. to treat and prevent influenza A.
Two other neuraminidase inhibitors are marketed outside the U.S. to treat and prevent influenza infection: PeramiFlu peramivir from BioCryst Pharmaceuticals Inc., Green Cross Corp. and Shionogi & Co. Ltd., and Inavir laninamivir from Daiichi Sankyo Co. Ltd. and Biota.

SciBX 6(10); doi:10.1038/scibx.2013.241
Published online March 14, 2013

Patent pending; available for licensing from CDRD Ventures Inc.

Kim, J.-H. et al. Science;
published online Feb. 21, 2013;
Contact: Stephen G. Withers,
The University of British Columbia, Vancouver, British Columbia, Canada